The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
N | Nervous system | |
2
|
N06 | Psychoanaleptics | |
3
|
N06D | Anti-dementia drugs | |
4
|
N06DX | Other anti-dementia drugs |
| Code | Title | |
|---|---|---|
| N06DX01 | Memantine | |
| N06DX02 | Ginkgo folium | |
| N06DX03 | ||
| N06DX04 | ||
| N06DX05 |
| Active Ingredient |
|---|
|
Donanemab is an immunoglobulin gamma 1 (IgG1) monoclonal antibody with high affinity for a modified, N-terminal truncated form of amyloid beta (N3pE Aβ). N3pE Aβ is present in brain amyloid plaques at low levels, and not detected in plasma and CSF. Donanemab binds to N3pE Aβ and aids plaque removal through microglial-mediated phagocytosis. |
|
The exact mechanism of action of ginkgo biloba is not known. Human pharmacological data show increased EEG vigilance in geriatric subjects, reduction in blood viscosity and improved cerebral perfusion in specific areas in healthy men (60-70 years) and reduction in platelet aggregation. Additionally, vasodilating effects on forearm blood vessels causing increased regional blood flow are shown. |
|
Lecanemab is an IgG1 monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta and reduces amyloid beta plaques. |
|
Memantine is a voltage-dependent, moderate-affinity uncompetitive NMDA-receptor antagonist. It modulates the effects of pathologically elevated tonic levels of glutamate that may lead to neuronal dysfunction. |
| Document | Type | Information Source | |
|---|---|---|---|
| AXURA Film-coated tablet | MPI, EU: SmPC | European Medicines Agency (EU) | |
| COGNIMET Film-coated tablet | MPI, Generic | Health Products Regulatory Authority (ZA) | |
| EBIXA Film-coated tablet | MPI, EU: SmPC | European Medicines Agency (EU) | |
| EBIXA Oral solution | MPI, EU: SmPC | European Medicines Agency (EU) | |
| KISUNLA Concentrate for solution for infusion | MPI, EU: SmPC | European Medicines Agency (EU) | |
| KISUNLA Solution for injection | MPI, US: SPL/PLR | FDA, National Drug Code (US) | |
| LEQEMBI Concentrate for solution for infusion | MPI, EU: SmPC | European Medicines Agency (EU) | |
| LEQEMBI Solution for injection | MPI, US: SPL/PLR | FDA, National Drug Code (US) | |
| NEMDATINE Film-coated tablet | MPI, EU: SmPC | European Medicines Agency (EU) |